| Breastfeeding and complementary food |
Food Allergy & Eosinophilic Diseases |
Hepatology |
Nutrition & intestinal rehabilitation |
| 1. Global challenges on Breast Feeding promotion |
1. Strategies to prevent Cow´s milk allergy: Are we doing our best? |
1. Where are in prevention and treatment of hepatitis B and C. |
1. Effective interventions to improve outcome in the malnourished child under 5 years of age in low- and middle-income countries |
| 2. Recent WHO Guidelines; Pros and Cons |
2. Advances in the treatment of IgE mediated food allergies |
2. Autoimmune hepatitis interplay with sclerosing colangitis and inflammatory bowel disease: Is it a progressive disease? |
2. Premature infant: implementing Individualized feeding plans and complementary food introduction |
| 3. If mom cannot breast feed |
3. New allergens in the horizon? |
3. Associated steatotic liver disease (ASLD): new approaches to understanding the disease in children and management |
3. Vitamin supplementation When? To whom ? |
| 4. Can we move forward to global recommendations with complementary food introduction ? |
4. Induction of cow milk protein tolerance in cow milk allergy: where are we? |
4. Portal hypertension in children: challenges and persistent dilemmas. |
4. Child with special nutritional requirements |
| Celiac & GRD |
5. Impact of food allergy on quality of life and financial burden: a worldwide perspective |
5. Biliary Atresia: advances in etiology, pathogenesis and long term follow up |
5. Childhood obesity: Epidemiology and pathogenesis |
| 1. Artificial intelligence and machine learning algorithms in the endoscopic and histopathological diagnosis and follow up of CD patients |
6. AllerStat: Search of allergen-specific patterns, allergenicity prediction and utility evaluation of synthetic foods and proteins |
6. Genetic liver diseases: Is there a new diagnostic algorithm? Is it feasible worldwide? |
6. Dietary interventions to prevent childhood obesity |
| 2. Can we move towards a global diagnostic process? |
7. Update on the epidemiology of Eosinophilic Esophagitis: What factors of change should we consider? |
7. Neonatal cholestasis: novel pharmacological therapies . Pros and Cont. |
7. Advances in treatment of pediatric obesity |
| 3. What about other autoimmunity pathologies in celiac disease? |
8. Current diagnostic approach of Eosinophilic Esophagitis |
8. Are risk factors for metabolic dysfunction–associated fatty liver disease alike in patients younger and older than 5? |
8. Exclusion diets : growth vs burden |
| 4. Screening for celiac disease in the general pediatric population: has the time come?. |
9. Gastrointestinal eosinophilic disease: beyond esophagitis |
9. Food insecurity and pediatric ASLD severity |
9. Facts and fiction ; vegetarian , veganism , gluten free , lactose free and more diets |
| 5. Something new in celiac disease follow-up? |
10. Are ESPGHAN/NASPGHAN Guidelines on Eosinophilic Gastrointestinal Disorders Beyond the Esophagus applicable around the world? |
10. How are ASLD diet therapies adapted to regional / local customs? |
10. New insights on “ healthy diets “ |
| 6. Are we overdiagnosing gluten related disorders? |
11. Therapeutic developments in eosinophilic esophagitis and their effectiveness |
11. Metabolic diseases and liver transplantation: never a living donor? |
11. Feeding disorders How to improve their every day life |
| 7. In GRD, are we talking about a transitory pathology or a lasting disorder? |
Enviromental and Global health |
12. Severe Acute Hepatitis: An Update |
12. Short bowel and intestinal adaptation |
| 8. Are there new tools to assess adherence to the gluten-free diet? |
1. Environmental Enteric Dysfunction, what are the roles of pathobionts in the pathogenesis? |
13. Sarcopenia in Children with Liver Disease: does it have an impact on follow-up or is it just an anthropometric measure? |
13. Teglutide use when and to whom ? |
| 9. New diagnostic challenges in GFD style era |
2. Emerging and old pathogens with digestive implications (TBC, chikungunya, etc) |
14. Porto Systemic Shunt: imaging tests and treatment guidelines |
14. Long term follow up on home parenteral nutrition |
| 10. Assessment of response in gluten challenge and clinical trials |
3. Antibiotic resistance and its relevance for GI infections including C difficile burden |
IBD |
15. Intestinal transplantation, elongation and combined surgical strategies |
| 11. From pathogenesis to novel therapies |
4. New Infections in Latin America |
1. Should we tailor small molecule vs. biologic therapeutic options in low- and middle-income areas? |
Pancreatology |
| 12. Argentinean experiences in new therapies. Probiotics and peptidases |
5. Climate, Enviromental contamination and global child health equity. |
2. How to define the predictive factors of response? How to select the 1st biological? |
1. Acute pancreatitis: An Update with severity predictors |
| 13. Is personalized medicine possible in celiac disease (predictors or interventions to prevent disease)? |
6. Innovations in Pediatric Global Health: the role of machine learning and AI in global child health |
3. What to do when we lose the response to biologicals? How to prevent and/or reverse the loss of response to biologics? |
2. Genetic studies in pancreatitis. Where we are? |
| Endoscopy |
7. Hunger and growth: Addressing food insecurity towards 2030 sustainable development goals. From undernutrition to obesity in childhood. |
4. The role of intestinal resection in Crohn"s disease (provocative studies like the lyric trial) and surgical decision-making in UC |
3. Therapeutic strategy in management of acute, recurrent and chronic pancreatitis |
| 1. A review of the New Era of Capsule Endoscopy |
8. H. pylori the bad guy: Associated diseases in children |
5. Diagnostic challenges in low and middle income areas |
4. Endoscopic approach in Chronic Pancreatitis |
| 2. Role of Pediatric Endosonography in today´s era |
9. H. pylori the good guy: Benefits of infection in modulating allergic and immune-mediated diseases |
6. New target , will they become an affordable option for low-income regions? |
Research & Future directions |
| 3. Endoscopic follow-up of patients with EoE: new guidelines and long-term alternatives |
10. H. pylori: Are the NASPGHAN/ESPGHAN Guidelines 2023 applicable around the world? |
7. How dietary therapies can be made region specific and adapted to foods available in diverse geographies |
1. Advances in Pediatric Acute Liver Failure (PALF): Failure to TRIUMPH. |
| 4. AI (Artificial Intelligence) in the Pediatric Endoscopy Room |
Gut Microbiota |
8. Monogenic disease VEOIBD the immunologist's vision |
2. To circulate around the gut, liver, and nutrition with microbiome |
| 5. New techniques and devices for non-variceal GI Bleeding |
1. Introduction to Microbiome for the pediatric gastroenterologist |
9. Do we have to consider a different diagnostic algorithm in VEOIBD? |
3. Optimal treatment in pediatric IBD, closing the gap via investigator initiated clinical research |
| 6. Endoscopic therapy for Obesity (balloons and others) |
2. Metagenome sequencing of the gut microbiome in populations all over the world |
10. Beyond Crohn disease ….. The dietary habits of patients with UC under follow-up in an IBD unit |
4. What is the key to research in developing countries? jumping the hurdles to go to growth |
| 7. Potential of balloon-assisted enteroscopy: What can we do with BAE? |
3. Impacts of the maternal microbiome on the developing infant across the perinatal period |
11. EUS-IBD, What can you tell us, Will it be essential in every medical visit? |
5. What news in hepatocyte transplantation? Is an opportunity for acute liver failure? |
| 8. Advanced polypectomy with EMR/ESD |
4. Opportunities for interventions (trials) |
12. Transition readness in youth with IBD |
6. What happens with chronic bowel inflammation. Where does it take to you? |
| 9. Endoscopic management of GI fistulae and perforations in children |
5. Cell viability: don´t give up! In the era of postbiotics. |
13. Fertility and breastfeeding still in our activity |
Transplant |
| 10. Endoscopic biliopancreatic interventions in children |
6. The fiability of HMO in different situations |
JPGN |
1. Pediatric waiting list mortality & amp; how to improve it |
| 11. Simulators and other trends in Endoscopy training |
7. The use of gum Arabic as natural prebiotic in the management of acute diarrhea |
1. Recognize publication topics of interest for JPGN and JPGN Reports |
2. Should living donor be almost always the first graft option in pediatric liver transplant candidate? |
| 12. Current situation of Endoscopy Training in Asian Pacific Region |
8. Diet-microbiota interaction: towards a personalized medicine |
2. Develop a manuscript plan to transform abstracts to publication at JPGN/JPGNR |
3. Technical variant grafts varies widely and impacts pediatric liver transplant waitlist and recipient outcomes in the United States |
| 13. New Colonoscopy quality indicators |
9. Give the bugs or feed the bugs? |
3. Determine an approach to common editorial issues |
4. Cardiovascular manifestation after Liver transplantation: An update |
| 14. A concise review and update on the spectrum of hereditary polyposis syndromes encountered in children with focus on key management considerations |
10. The Future of Gastrointestinal Health: Predicting and Preventing Disease with Microbiotic Profiling |
Neurogastroenterology & motility |
5. LDLT in the setting of ACLF |
| 15. Extracolonic Cancer Surveillance in Pediatric Polyposis, Guidelines and Beyond |
|
1. Where will the Rome V Criteria go? |
6. What the pandemic taught us: Vaccination or more |
| 16. Familial Adenomatous Polyposis, Keeping the Colon |
|
2. What to do with functional nausea? |
7. Outcomes after a long-term of pediatric liver transplantation |
| 17. Psychosocial Challenges and Transition of Care in Children with Polyposis |
|
3. Should biliary disorders be considered in pediatrics within the DGBIs? |
Transition to adult care |
| 18. Polypectomy and Advanced Techniques |
|
4. EndoFLIP (Endoluminal functional lumen imaging probe) in pediatrics |
1. Adherence, Costs and Providers: Approach for an adolescent in Transition |
| |
|
5. Pelvic floor therapy: new therapeutic/preventive |
2. Family and transition. A Broad vision |
| |
|
6. DGBIs from childhood to adulthood: the transition |
3. Quality of life and transition. Two ends of the same skein? |
| |
|
7. Gastroparesis versus Functional dyspepsia |
4. Adult perspective view |
| |
|
8. Refractory constipation:medical and surgical treatment |
Young Career & Training Program |
| |
|
9. Psychotherapy, hipnotherapy, food and drugs in motility disorders |
1. Naspghan Experience with EPA |
| |
|
10. Central Neuromodulators in the treatment of DGBIs |
2. Training abroad and returning to your home country |
| |
|
11. Nutritional approach in DGBI disorders |
3. Developing research in resource limited areas a tool for global equity |
| |
|
12. The unavoidable pandemic of DGBI |
4. Building Global Networks: Latin America´s Vision for worldwide Gastroenterology Education |
| |
|
13. Neurostimulation in pediatric DGBI |
|
